Announcement on Progress in Wholly-owned Subsidiary’s Clinical Trial for VUM02 Injection
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Filed with SSE · · 3 pages · Chinese
The clinical trial has officially started with the first subject receiving treatment, marking the initiation of Phase Ib/II trials. The announcement includes details about the drug's specifications and its registration as a therapeutic biological product. The company emphasizes the need for clinical trials and regulatory approval before the drug can be marketed.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
On 6ix: 6ix.com/news/announcement-on-progress-in-wholly-owned-subsidiarys-clinical-trial-for-vum02-injection
Announcement on Progress in Wholly-owned Subsidiary’s Clinical Trial for VUM02 Injection
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Vcanbio Cell & Gene Engineering Corp., Ltd. on 6ix
Follow Vcanbio Cell & Gene Engineering into a list and get an email when it puts out news.
Follow Vcanbio Cell & Gene Engineering